Andere talen Zydus Lifesciences Limited

Aandelen

ZYDUSLIFE

INE010B01027

Beurs gesloten - NSE India S.E. Andere beurzen 13:43:49 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
947,4 ^INR	-0,40%		+2,74%	+37,46%

26/04	Zwakke kwartaalcijfers wegen vrijdag op Indiase aandelen	MT
26/04	Zydus Lifesciences krijgt definitieve goedkeuring van de Amerikaanse FDA voor generieke acnecrème	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Weak March Quarter Earnings Weigh Down Indian Equities on Friday	26/04
Zydus Lifesciences Gets US FDA's Final Approval for Generic Acne Cream	26/04
Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	24/04
China Medical System's Anti-Anaemia NDA Accepted in China	23/04
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23/04
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	23/04
Zydus launches Mirabegron Extended-Release Tablets in the US	22/04
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	22/04
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	22/04
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	22/04
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	01/04
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	28/03
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	23/03
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	18/03
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	16/03
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	15/03
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	14/03
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	14/03
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	14/03
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	13/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Zydus Lifesciences Limited

Aandelen

ZYDUSLIFE

INE010B01027

Andere talen

Filters